PROK
ProKidney Corp.
$2.19
+$0.10(+4.78%)
25
Overall
40
Value
10
Tech
--
Quality
Market Cap
$685.90M
Volume
1.53M
52W Range
$0.46 - $7.13
Target Price
$5.40
Company Overview
| Mkt Cap | $685.90M | Price | $2.19 |
| Volume | 1.53M | Change | +4.78% |
| P/E Ratio | -11.2 | Open | $2.08 |
| Revenue | $76.0K | Prev Close | $2.09 |
| Net Income | $-61.2M | 52W Range | $0.46 - $7.13 |
| Div Yield | N/A | Target | $5.40 |
| Overall | 25 | Value | 40 |
| Quality | -- | Technical | 10 |
No chart data available
About ProKidney Corp.
ProKidney Corp., a clinical-stage biotechnology company, develops a cell therapy platform for the treatment of multiple chronic kidney diseases in the United States. Its lead product candidate, rilparencel, includes autologous selected renal cells (SRC) in Phase 3 and Phase 2 clinical studies in subjects with moderate to severe chronic kidney disease and diabetes. The company also develops a cryopreserved version of rilparencel that allows for long-term product preservation to be used in Phase 2 and 3 trials of rilparencel. ProKidney Corp. founded in 2015 and is based in Winston-Salem, North Carolina.
Latest News
Bank of America Securities Keeps Their Sell Rating on ProKidney (PROK)
TipRanks Auto-Generated Intelligence Newsdesk•11 days ago
Prokidney’s REACT Study: A Potential Game Changer for Kidney Disease Treatment
TipRanks Clinical-Trials-Auto-Generated Newsdesk•a month ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | PROK | $2.19 | +4.8% | 1.53M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |